Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Pharmaceutical Statistics|October 23, 2010
A course for clinical trial personnel in clinical study designs, randomization, allocation schedules, and interactive response systemsGregory T Golm, Thomas E Bradstreet, Laura A Coffey
Statistical Theory and Related Fields|May 27, 2024
Robust analyzes for longitudinal clinical trials with missing and non-normal continuous outcomesSiyi Liu, Yilong Zhang, Gregory T Golm, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 24, 2013
Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studiesSamuel S Engel, Elizabeth Round, Gregory T Golm, et al.
Cardiovascular Diabetology|January 5, 2013
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisSamuel S Engel, Gregory T Golm, Deborah Shapiro, et al.
Drugs & Aging|February 11, 2014
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studiesElizabeth M Round, Samuel S Engel, Gregory T Golm, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 13, 2013
Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metforminSamuel S Engel, Thomas L Seck, Gregory T Golm, et al.
Drugs & Aging|June 5, 2015
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority TrialPaul Hartley, Yue Shentu, Patricia Betz-Schiff, et al.
Diabetes Care|December 19, 2012
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyJuan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, et al.
Journal of Diabetes and Its Complications|November 3, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetesVivian Fonseca, Bart Staels, Jerry D Morgan, et al.
Diabetes Research and Clinical Practice|April 12, 2011
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizideThomas L Seck, Samuel S Engel, Debora E Williams-Herman, et al.
Pageof 3